Takeda Expands HAE Treatment Options with New TAKHZYRO® Pre-Filled Pen

Takeda has announced that the European Medicines Agency (EMA) has approved a new 2 mL pre-filled pen for TAKHZYRO® (lanadelumab), providing an additional subcutaneous administration option for adolescents and adults with hereditary angioedema (HAE). This approval marks an important milestone in Takeda’s ongoing efforts to offer more flexible and individualized treatment options for patients with this rare but life-threatening condition. The new pre-filled pen simplifies administration, potentially improving adherence and quality of life for those managing HAE.

HAE is often underdiagnosed and can have a significant impact on daily life. With this expanded treatment option, Takeda continues to strengthen its leadership in HAE management, ensuring that patients receive effective and convenient care. “The EMA’s swift approval underscores the importance of providing more administration choices for HAE patients,” said Irmgard Andresen, Global Medical Lead for HAE at Takeda. This latest advancement aligns with Takeda’s broader mission to develop innovative solutions for underserved patient populations.